Participant flow14

How many started, completed or left each group, period by period.

1 to 14 of 14

Period	Milestone	Group	Participants
Placebo Controlled Period	STARTED	Solanezumab	1,057
Placebo Controlled Period	STARTED	Placebo	1,072
Placebo Controlled Period	Received at Least 1 Dose of Study Drug	Solanezumab	1,054
Placebo Controlled Period	Received at Least 1 Dose of Study Drug	Placebo	1,067
Placebo Controlled Period	COMPLETED	Solanezumab	914
Placebo Controlled Period	COMPLETED	Placebo	908
Placebo Controlled Period	NOT COMPLETED	Solanezumab	143
Placebo Controlled Period	NOT COMPLETED	Placebo	164
Open Label Period	STARTED	Solanezumab	881
Open Label Period	STARTED	Placebo	859
Open Label Period	COMPLETED	Solanezumab	0
Open Label Period	COMPLETED	Placebo	0
Open Label Period	NOT COMPLETED	Solanezumab	881
Open Label Period	NOT COMPLETED	Placebo	859

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01900665/flow